MAP2 and delirium: Indeed, treatment of cells with an antibody against IL13 prevented the decrease in neurogenesis (DCX, Map2) and increase in apoptosis (CC3) caused by treatment with serum from delirium patients (Time point 1, delirium vs delirium + IL13 antibody; for DCX, 19.1% vs 33.8%, p < 0.0001; for Map2, 25.1% vs 41.4%, p < 0.0001; for CC3, 17.3% vs 3.8%, p < 0.0001).